Clinical Infectious Diseases APC and Open Access: Current OUP Pricing, Page Charges, and When Gold OA Is Worth It

CID's current OUP author-guidelines page is much more specific than the older generic APC summaries:

• USD 5,201 regular charge for OA licensing in OUP's charge data (read 2026-10-09), while the author guidelines print USD 5,001

• USD 125 per finished page in page composition charges

• USD 550 per printed color figure for non-OA papers that print in color

• no waivers for OA licensing

• read and publish agreements may still cover the OA charge

• 12-month embargo for public-access release of funded papers through the standard route

That creates the real route menu:

This is one of the clearest examples in the whole APC family where society-journal economics are more complicated than the APC headline suggests.

The APC is attached to a journal that still has strong clinical consequence. That matters because access decisions at CID are often about real guideline, stewardship, and care-pathway visibility rather than abstract prestige.

The year-over-year move is negative. CID is down from 11.8 in 2023 to 7.3 in 2024, which is best read as post-pandemic normalization rather than collapse. The five-year JIF staying near the two-year figure is the more useful signal for authors.

At many hybrid journals, choosing the standard route genuinely avoids the main bill. At CID, that is only partly true because page composition charges still survive either way.

That matters in practice:

• a long paper can generate a meaningful page-charge invoice

• OA does not erase the page-composition line item

• non-OA print color can add another charge that OA papers avoid

So the real comparison is:

• OA route: large licensing charge plus page composition

• standard route: no OA licensing charge, but still page composition and possible print color cost

This makes CID's economics unusually sensitive to article length.

Across Manusights submission reviews, CID is one of the few APC pages where article length changes the recommendation materially. A short concise report with strong institutional OA support can make the gold route feel straightforward. A long clinical paper with many tables can look very different once the page-composition bill is added on top of the OA charge.

That means the real budgeting sequence is:

• estimate the likely finished page count

• decide whether the paper genuinely needs immediate final-version access

• check whether your institution covers OUP hybrid OA

If the paper is long and institutional coverage is absent, the standard route plus later public-access release is often the more rational choice unless the paper has clear guideline or policy visibility that genuinely benefits from immediate open access.

In our pre-submission review work, the biggest mistake is not underestimating the APC. It is treating CID like a generic medicine journal instead of a clinical-ID decision journal.

What usually works:

• clearly practice-relevant clinical ID studies

• patient-level consequence that infectious-disease physicians care about

• stewardship, treatment, diagnostics, or epidemiology with clear actionability

What usually creates regret:

• clinically adjacent papers without a real ID practice consequence

• microbiology-first manuscripts with weak clinical framing

• discussing the OA bill before deciding whether the study actually deserves a CID audience

That is why the journal's published timing split is so useful. CID is fast at telling you when the paper is not really a CID paper.

For Clinical Infectious Diseases APC, the useful 2026 correction is:

• OA licensing charge: USD 5,201 in OUP's charge data (read 2026-10-09); the author guidelines print USD 5,001

• page composition: USD 125 per finished page either way

• non-OA print color: additional cost if you want color in print

• OA waiver policy: no waivers for OA licensing

So the decision is not just whether the paper should be open. It is whether immediate final-version openness is worth paying for once the unavoidable page charges are already in view.